Sensitivity evaluation of methods for screening JAK2 exon 12 mutations based on heteroduplex and HRM analysis

Background. According to WHO guidelines, one of the criteria for diagnosis of polycythemia vera is the presence of somatic mutations in exon 12 of the JAK2 gene, but to date there is no universally accepted simple method to analyze these mutations. We have previously proposed two methods for screening such mutations based on heteroduplex and HRM (High Resolution Melt) assays, which are relatively cheap and fast compared to sequencing.

Aim. To analyze the sensitivity of these screening methods.

Materials and methods. The study used cloned DNA samples from 6 patients with various mutations in exon 12 of the JAK2 gene that we had previously identified, as well as a clone of the corresponding wild-type DNA segment. Dilution of the cloned mutant samples with wild-type clones was performed to obtain samples with different levels of allele burden: 100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 0.78 %. Heteroduplex analysis followed by PAGE (polyacrylamide gel) and HRM analysis was then performed with the diluted samples.

Results. The sensitivity threshold of the heteroduplex analysis was found to be between 3.13–6.25 % allele burdens depending on the specific mutation, the sensitivity threshold of the HRM assay was 6.25–12.5 % similarly.

Conclusion. Our proposed methods of heteroduplex analysis followed by PAGE and HRM-analysis for the detection of polycythemia vera-specific mutations in exon 12 of the JAK2 gene allow increasing the efficiency of using different types of sequencing and can be used as simpler and less expensive methods of preliminary screening of these mutations.

1. Bose P., Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol 2019;10:2040620719870052. DOI: 10.1177/2040620719870052

2. Maddali M., Kulkarni U.P., Ravindra N. et al. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis. Ann Hematol 2020;99(5):983–9. DOI: 10.1007/s00277-020-04004-7

3. Scott L.M. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011;86(8):668–76. DOI:10.1002/ajh.22063

4. Tondeur S., Paul F., Riou J. et al. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia 2021;35(3):871–5. DOI:10.1038/s41375-020-0991-x

5. Silvennoinen O., Hubbard S.R. Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood 2015;125(22):3388– 92. DOI: 10.1182/blood-2015-01-621110

6. Subbotina T.N., Kharsekina A.E., Dunaeva E.A. et al. Heteroduplex analysis and pyrosequencing in the diagnostic algorithm of polycythemia vera associated with JAK2 exon 12 mutations. Laboratornaya sluzhba = Laboratory Service 2017;6(1):29–33. (In Russ.). DOI: 10.17116/labs20176129-33

7. Kurochkin D., Maslyukova I., Subbotina, T. et al. P1056: screening of JAK2 exon 12 somatic mutations by high-resolution melting curve analysis. HemaSphere 2022;6:946–7. DOI: 10.1097/01.HS9.0000847092.01448.ed

8. Subbotina T.N., Dunaeva E.A., Mironov K.O. et al. Using of pyrosequencing method for the detection and quantitative determination of mutant JAK2 exon 12 allele burden. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2016;61(4):196–200. (In Russ.). DOI: 10.18821/0234-5730-2016-61-4-196-200

9. Sambrook J., Russell D. Molecular cloning: a laboratory manual. 3rd edn. Cold Spring Harbor Laboratory Press, 2001.

10. Jones A.V., Cross N.C., White H.E. et al. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica 2008;93(10):1560–4. DOI: 10.3324/haematol.12883

11. Pietra D., Li S., Brisci A. et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111(3):1686–9. DOI: 10.1182/blood-2007-07-101576

12. Furtado L.V., Weigelin H.C., Elenitoba-Johnson K.S. et al. A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations. J Mol Diagn 2013;15(5):592–9. DOI: 10.1016/j.jmoldx.2013.04.006